GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » EPS without NRI

OncoSec Medical (FRA:ONMA) EPS without NRI : €-14.83 (TTM As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical EPS without NRI?

OncoSec Medical's earnings per share without non-recurring items for the three months ended in Jan. 2023 was €-2.46. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2023 was €-14.83.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for OncoSec Medical's EPS without NRI or its related term are showing as below:

FRA:ONMA's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.85
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

OncoSec Medical's EPS (Diluted) for the three months ended in Jan. 2023 was €-2.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2023 was €-14.83.

OncoSec Medical's EPS (Basic) for the three months ended in Jan. 2023 was €-2.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2023 was €-14.83.


OncoSec Medical EPS without NRI Historical Data

The historical data trend for OncoSec Medical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical EPS without NRI Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -183.61 -84.19 -49.00 -25.50 -18.82

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.90 -3.26 -4.54 -4.57 -2.46

Competitive Comparison of OncoSec Medical's EPS without NRI

For the Biotechnology subindustry, OncoSec Medical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's PE Ratio without NRI falls into.



OncoSec Medical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoSec Medical  (FRA:ONMA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


OncoSec Medical EPS without NRI Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines